Skip to main content

Table 1 Patient data during the clinical trial of Panagen

From: Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen

Patient number Breast cancer stage 1 year 1.5 years 2 years 3–4 years 5 years
FAC chemotherapy + Placebo
 01–03 T2N1M0 IIB remission remission remission remission remission
 01–08 T2N0M0 IIA remission remission remission remission remission
 01–12 T4N3M1 IV remission remission disease progression deceased
 01–16 T4N2M0 IIIB remission remission deceased (cause of death is not cancer) - -
 01–23 T4N0M0 IIIB remission remission disease progression no data no data
 02–07 T4N2M0 IIIB deceased - - - -
 02–12a T2N2M0 IIIA remission remission no data no data no data
 02–13 T4N3M0/1 IV therapy continues disease progression, lung metastases deceased - -
 02–17 T2N1M0 IIB remission remission remission remission remission
AC chemotherapy + Placebo
 02–23a T2N1M0/1 IV disease progression, lymph node metastases before the study + bone metastases deceased - - -
 02–32 T4NxM0 IIIB remission remission remission remission no data
 02–34 T4N2M0 IIIB disease progression, metastases to bones, lungs, and soft tissues of the chest wall no data no data no data no data
 02–35a T4NxM0 IIIB remission no data no data deceased -
 02–37a T4N0M0 IIIB disease progression, brain, lungs, liver and bone metastases deceased - - -
 02–38 T2N2M0 IIIA no data deceased - - -
 02–41 T1N1M0 IIA remission remission remission remission no data
FAC chemotherapy + Panagen
 01–01 T1N2M0 IIIA remission remission remission disease progression no data
 01–02 T1N2M0 IIIA remission remission remission disease progression no data
 01–04 T4N2M1 IV remission remission remission deceased -
 01–05 T2N1M0 IIB remission deceased - - -
 01–06 T4N1M0 IIIB remission remission remission remission remission
 01–07 T3N0M0 IIB remission remission remission remission remission
 01–09 T2N2M0 IIIA remission remission remission no data no data
 01–10 T4N3M0 IIIC remission remission remission remission no data
 01–11 T2N1M0 IIB remission remission remission remission no data
 01–13 T4N3M0 IIIC remission remission remission remission remission
 01–14 T4N2M0 IIIB remission remission remission disease progression deceased
 01–15 T2N2M0 IIIA remission remission remission remission remission
 01–17 T2N1M0 IIB remission remission remission no data no data
 01–18 T4N1M0 IIIB disease progression no data no data no data alive
 01–19 T4N1M0 IIIB remission remission remission deceased
 01–20 T2N0M0 IIA remission remission remission remission remission
 01–21 T4N3M0 IIIC disease progression no data no data alive alive
 01–22 T4N1M1 IV remission remission remission disease progression deceased
 02–01 T4NxM0 IIIB no data no data no data disease progression, tumor disintegration, multiple metastases in lungs deceased
 02–02 T2N0M0 IIA remission remission remission no data no data
 02–03 T1N1M0 IIA remission remission remission disease progression, Th11 metastases no data
 02–04 T3N2M1 IV deceased - - - -
 02–05 T4N1M0 IIIB remission remission remission remission remission
 02–06 T4NxM1 IV deceased - - - -
 02–08 T4N1M0 IIIB remission remission remission disease progression, lung, pleura and liver metastases no data
 02–09 T1N1M0/1 IV disease progression, bone metastases observed during the 1st CT round alive alive deceased -
 02–10 T1N1M0 IIA remission remission remission remission remission
 02–11a T2N1M0 IIB remission remission remission remission remission
 02–14 T2N2M0dex T4N1M0sin IIIB remission remission remission remission remission
 02–15 T3N2M0 IIIA remission remission remission remission remission
 02–16a T4NxM0 IIIB remission disease progression, metastases in the skin region adjacent to surgery scar partial regression deceased -
 02–18a T4NxM0 IIIB remission remission remission remission remission
AC chemotherapy + Panagen
 02–20 T2N1M0 IIB remission remission remission disease progression, bone metastases no data
 02–21 T2N0M0 IIA remission remission remission remission no data
 02–22a T2N1M0 IIB remission remission remission remission no data
 02–24 T2N1M0 IIB remission remission remission remission no data
 02–25a T2N2M0 IIIA remission remission remission remission no data
 02–26 T1N1M0 IIA remission remission remission remission no data
 02–27 T1N2M0 IIIA remission remission disease progression, bone metastases no data no data
 02–28a T2N1M0 IIB remission remission disease progression, bone and lung metastases no data no data
 02–29 T2N0M0 IIA remission remission no data deceased -
 02–30 T2NxM0 II remission remission remission remission no data
 02–31 T2N1M0/1 IV disease progression, lung metastases observed 1 month following completion of the therapy no data no data no data no data
 02–33a T2N3M0 IIIC remission remission remission remission no data
 02–36 T4NxM0dex T2NxM0sin IIIB treatment continues treatment continues no data no data no data
 02–39 T2N3M0 IIIC remission remission relapse no data no data
 02–40a T2N1M0 IIB remission no data no data no data no data
 02–42a T1N3M0 IIIC remission remission remission remission no data
 02–43 T3N0M0 IIB remission remission remission remission no data
 02–44a T1N1M0/1 IV disease progression, bone metastases observed after the 2ndCT round no data no data no data no data
 02–45a T4N1M0 IIIB remission remission disease progression, pleural metastases no data no data
  1. Note: a – tamoxifen treatment. CT chemotherapy. Patients who progressed or died are shown in boldface. Cause of death in all cases is breast cancer, except patient 01–16. Patient 01–16, whose cause of death was not cancer, didn’t taken into account further